.25mg semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) This medication is used with a doctor UK approves first weight-loss tablet

Depending on the peptide, significant potency can be lost in a matter of hours, not days

These medications bind to GLP-1 receptors in multiple tissues, producing several therapeutic effects

Rafraf M, Karimi M, Jafari A

"To know what you know and what you do not know, that is true knowledge." Confucius The gap between work as imagined and work as done is exactly where harm enters

Week two: finding your rhythm By the second week, the initial novelty wears off and you begin adjusting: Side effects may peak : For some patients, GI symptoms like nausea or bloating are at their worst during the first two weeks, then begin to fade